Incidence of cutaneous complications in advanced solid cancer patient treated with epidermal growth factor receptor inhibitors

Not Applicable

• Conditions: advanced solid cancer patientsepidermal growth factor receptor inhibitorsacneiform eruptionparonychiahair abnormalitiesskin drynesspruritus; EGFR inhibitors; radiotherapy; conventional chemotherapy; acneiform eruption; paronychia; hair abnormalities; skin dryness; pruritus

• Registration Number: TCTR20170727001
• Lead Sponsor: Quality Improvement Fund, King Chulalongkorn Memorial Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-07-27
• Study Completion: 2018-09-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

- advanced solid cancer patients (stage IV) treated with epidermal growth factor receptor inhibitors
- above 18 years old

Exclusion Criteria

prior to recruit in the study, patients have existing skin conditions including acneiform eruption, paronychia, hair abnormalities, skin dryness and pruritus.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
incidence of cutaneous complications in advanced solid cancer patients treated with EGFRI 2 weeks,4 weeks, 12 weeks, 24 weeks, 48 weeks Clinical manifestation of skin.

Secondary Outcome Measures

Name	Time	Method
changes of biophysical properties of the skin in advanced solid CA patients treated with EGFRI 2 weeks, 4 weeks, 12 weeks, 24 weeks, 48 weeks multi probe system Cutometer MPA580, Visia, Visiometer SV 600